Clinical trials: Non-Alcoholic Steatohepatitis
NASH - Nonalcoholic Steatohepatitis
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
- Trial name
- HM-TRIA-201 (NCT04505436)
- Testing
- HM15211
- Where
- 60 sites in United States, South Korea
- Volunteers
- 215 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Non-Alcoholic Fatty Liver Disease (NAFLD)
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
This study is to assess the effect of PF 05221304 alone, PF 06865571 alone, the co administration of PF 05221304 and PF 06865571, or placebo on whole liver fat in subjects with NAFLD.
- Trial name
- NCT03776175
- Testing
- PF-05221304 Monotherapy, PF-06865571 Monotherapy, PF-05221304 and PF-06865571 Combination
- Where
- 29 sites in United States
- Volunteers
- 99 people
- Sponsor
- Pfizer
Nonalcoholic Fatty Liver Disease
The University of Michigan Wellness for Liver Health Study
The goal of this proposal is to pilot test our existing very-low carbohydrate diet intervention, adapted for adults with Non-alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT05010070
- Testing
- diet and lifestyle program
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Epilepsy, Cardiovascular Disease
Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy
The ketogenic diet is a non-pharmacological treatment prescribed especially for children and indicated in most specialized centers for patients with refractory epilepsy.
- Conditions
- Epilepsy, Cardiovascular Disease, Non-alcoholic Fatty Liver Disease, Quality of Life
- Trial name
- Ketonutri (NCT02644239)
- Testing
- ketogenic diet
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Background: The COVID-19 global pandemic killed more than 6 million people worldwide. Several vaccines have been developed against the virus that causes this disease.
- Conditions
- Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD
- Trial name
- NCT05669677
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and liver cirrhosis (liver damage…
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
- Trial name
- FALCON 2 (NCT03486912)
- Testing
- BMS-986036
- Where
- 91 sites in United States, Japan
- Volunteers
- 155 people
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Calcification
Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification
Coronary artery disease are 8 times more prevalent in patients with NAFLD then the general population and are being considered the most common cause of death.
- Trial name
- NCT01158066
- Testing
- CT Cardiac
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Ziv Hospital
Liver Diseases
S.P.PRO LIVER POWDER is Used to Improve Liver and Metabolic Indexes in People With Non-alcoholic Fatty Liver Disease
With the Westernization of the diet and insufficient exercise, Taiwan's population of obesity, diabetes, and hyperlipidemia has increased in recent years, and the prevalence of the non-alcoholic fatty liver disease has gradually…
- Trial name
- NCT04718051
- Testing
- Shen Pu Yang Gan Wan
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University WanFang Hospital
NASH
Misoprostol for NASH
The aim of this randomised control trial is to evaluate the effect of Misoprostol in treating patients with NASH.
- Trial name
- NCT05804305
- Testing
- Misoprostol
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Ziauddin University
Non Alcoholic Fatty Liver Disease
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in Non Alcoholic Fatty Liver Patients Treating with…
- Trial name
- NCT02178839
- Testing
- β- glucan, Maltodextrin
- Where
- Iran
- Volunteers
- 48 people
- Sponsor
- Urmia University of Medical Sciences
Fatty Liver Disease
Epidemiological Survey on Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
To investigate the prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) among adults in China
- Trial name
- MAFLD (NCT05421572)
- Testing
- Fibrotouch
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Liver Diseases, Liver Cirrhosis
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
The main objective of the study is to determine the diagnostic performances of an ultraportable diagnostic ultrasound system for the assessment of liver fibrosis severity in patients with NASH, and to compare them to other…
- Conditions
- Liver Diseases, Liver Cirrhosis, NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease
- Trial name
- POCUS-NASH (NCT05120557)
- Testing
- Ultrasound liver assessment
- Volunteers
- 1,000 people
- Sponsor
- E-Scopics
Non-Alcoholic Fatty Liver Disease
Investigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease
To identify key characteristics of the tissue resident and peripherally circulating immune-phenotype in addition to blood markers, metabolic profile, faecal and oral microbiota in non-alcoholic fatty liver disease
- Trial name
- NCT04141592
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Queen Mary University of London
Non-Alcoholic Fatty Liver Disease
Cold-induced Brown Fat Activation and Hepatic Steatosis
In the recent years, research on brown adipose tissue (BAT) revealed that larger amounts as well as higher activity thereof are associated with a favourable metabolic phenotype.
- Trial name
- NCT03811236
- Testing
- Cold exposure
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Medical University of Vienna
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan
Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic disorder prevalent among women of reproductive age. It is closely associated with insulin resistance, obesity, and metabolic dysfunction, often leading to…
- Trial name
- NCT07027332
- Testing
- FibroScan® (Echosens, Paris, France)
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Non Alcoholic Steatohepatitis
Coffee Consumption and NASH in the French Population.
The aim of our study is to evaluate the effect of coffee consumption on the risk of severe liver fibrosis in French patients with NASH.
- Trial name
- COCANASH (NCT03432377)
- Where
- 16 sites in France
- Volunteers
- 107 people
- Sponsor
- Versailles Hospital
Cardiovascular Diseases, Osteoporosis
Guangzhou Nutrition and Health Study (GNHS)
Purpose: The Guangzhou Nutrition and Health Study (GNHS) project aims to assess the determinants of metabolic disease in nutritional aspects, as well as other environmental and genetic factors, and explore possible mechanisms…
- Conditions
- Cardiovascular Diseases, Osteoporosis, Diabetes Mellitus, Type 2, Metabolic Syndrome
- Trial name
- GNHS (NCT03179657)
- Volunteers
- 5,118 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2, NAFLD
Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients
Patients with type 2 diabetes and non-alcoholic fatty liver disease will be enrolled. According to a parallel design, the participants will be randomized to a Portfolio diet or a monounsaturated fatty acid (MUFA)-rich diet (used…
- Trial name
- MEDEA (NCT03380416)
- Testing
- Portfolio Diet, MUFA Diet
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Federico II University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.